Main |
Browse Volumes |
Forthcoming Volumes |
Annals PrePrints |
Annals Extra |
E-mail Alerts |
Subscriptions & Orders |
New Proposals |
Author Guidelines |
About Annals |
Help |
 |
|
|
|
|
|
Is the Estrogen Controversy Over? Deconstructing the Women's Health Initiative Study: A Critical Evaluation of the Evidence
S MITCHELL HARMANa,
FREDERICK NAFTOLINb,
ELIOT A. BRINTONc AND
DEBRA R. JUDELSONd
aKronos Longevity Research Institute, Phoenix, Arizona 85016, USA
bYale University College of Medicine, New Haven, Connecticut 06511, USA
cUniversity of Utah School of Medicine, Salt Lake City, Utah 84112, USA
dWomen's Heart Institute, Cardiovascular Medical Group of Southern California, Beverly Hills, California 90210, USA
Address for correspondence: S. Mitchell Harman, M.D., Ph.D., Kronos Longevity Research Institute, 2222 E. Highland, Ste. 220, Phoenix, AZ 85016. Voice: 602-778-7484; fax: 602-778-7485. mitch.harman{at}kronosinstitute.org
The Women's Health Initiative (WHI) hormone trials have been widely interpreted as demonstrating that combined menopausal hormone therapy (HT) fails to protect against—and may increase—cardiovascular disease (CVD), stroke, and dementia in menopausal women, regardless of whether initiated early in the menopause or later. This conclusion does not agree with results of large epidemiological studies showing protection by HT and by estrogen replacement alone (ET) against CVD and dementia. One possible reason for this inconsistency is that the epidemiologic data are confounded by "healthy user bias." Another possible explanation is that most women in the observational studies initiated ET or HT at or near the menopausal transition, at which point there is little or no arterial injury, whereas, in the WHI studies, older women, averaging approximately 12 years postmenopausal, many of whom would have had significant asymptomatic atherosclerosis, were treated. Substantial data demonstrate atheropreventive effects of estrogen before vascular damage occurs, whereas adverse effects of oral estrogen on thrombosis and inflammation may predominate once complex atheromas are present. Similarly, the excess of dementia observed in older WHI women treated with oral conjugated estrogen could be due to cerebral thromboses (multi-infarct dementia). Given the uncertain relevance of the WHI (and other published randomized clinical trials) to initiation of HT in perimenopausal women, and its subsequent continuation for atheroprevention, new trials will be needed to resolve whether early intervention with estrogen may prevent CVD and/or dementia. The Kronos Early Estrogen Prevention Study (KEEPS), which began in mid-2005, is a randomized, controlled multicenter trial of HT in recently menopausal women. It will examine surrogate end points as well as risk factors for atherosclerosis.
Key Words: menopause • estrogen • hormone therapy • atherosclerosis • cardiovascular disease • dementia
This article has been cited by other articles:
|
|
|
|
 
N. Krieger
Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections
Int. J. Epidemiol.,
March 28, 2008;
(2008)
dyn055v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schulkin
Hormone Therapy, Dilemmas, Medical Decisions.
J. Law Med. Ethics,
March 1, 2008;
36(1):
73 - 88.
[PDF]
|
|
|
|
|
|
|
E. Barrett-Connor
Hormones and Heart Disease in Women: The Timing Hypothesis
Am. J. Epidemiol.,
September 1, 2007;
166(5):
506 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sherwood, J. K. Bower, J. McFetridge-Durdle, J. A. Blumenthal, L. K. Newby, and A. L. Hinderliter
Age Moderates the Short-Term Effects of Transdermal 17{beta}-Estradiol on Endothelium-Dependent Vascular Function in Postmenopausal Women
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2007;
27(8):
1782 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schumacher, R. Guennoun, A. Ghoumari, C. Massaad, F. Robert, M. El-Etr, Y. Akwa, K. Rajkowski, and E.-E. Baulieu
Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System
Endocr. Rev.,
June 1, 2007;
28(4):
387 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Suzuki, C. M. Brown, C. D. Dela Cruz, E. Yang, D. A. Bridwell, and P. M. Wise
Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions
PNAS,
April 3, 2007;
104(14):
6013 - 6018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Dahlman-Wright, V. Cavailles, S. A. Fuqua, V. C. Jordan, J. A. Katzenellenbogen, K. S. Korach, A. Maggi, M. Muramatsu, M. G. Parker, and J.-A. Gustafsson
International Union of Pharmacology. LXIV. Estrogen Receptors
Pharmacol. Rev.,
December 1, 2006;
58(4):
773 - 781.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hayashi, H. Matsui-Hirai, A. Miyazaki-Akita, A. Fukatsu, J. Funami, Q.-F. Ding, S. Kamalanathan, Y. Hattori, L. J. Ignarro, and A. Iguchi
Endothelial cellular senescence is inhibited by nitric oxide: Implications in atherosclerosis associated with menopause and diabetes
PNAS,
November 7, 2006;
103(45):
17018 - 17023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Singh, J. A. Dykens, and J. W. Simpkins
Novel Mechanisms for Estrogen-Induced Neuroprotection.
Experimental Biology and Medicine,
May 1, 2006;
231(5):
514 - 521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Duckles, D. N. Krause, C. Stirone, and V. Procaccio
Estrogen and mitochondria: a new paradigm for vascular protection?
Mol. Interv.,
February 1, 2006;
6(1):
26 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
